Cardio-oncology in targeting the HER receptor family: The puzzle of different cardiotoxicities of HER2 inhibitors

Adriana Albini, Eugenio Cesana, Francesco Donatelli, Rosaria Cammarota, Eraldo O. Bucci, Massimo Baravelli, Claudio Anzà, Douglas M. Noonan

Research output: Contribution to journalArticle

Abstract

The HER family of tyrosine kinase receptors includes several members that are clinically important targets in cancer therapies, in particular HER1 (the EGF receptor) and HER2, other members include HER3 and HER4. Trastuzumab, a humanized monoclonal antibody and lapatinib, a tyrosine kinase inhibitor, are drugs that target HER2, which is highly expressed in 20-30% of breast cancers. Trastuzumab is recommended as an adjuvant therapy for lymph node positive, HER2-positive breast cancers, or node-negative cancer with high-risk of recurrence, as well as in stage IV cancers. One serious side effect of trastuzumab is cardiomyocyte dysfunction, resulting in reduced heart contractile efficiency. The incidence of collateral effects on the heart with trastuzumab therapy increases in people with cardiovascular risk factors, heart disease and when combined with other chemotherapeutics. When cardiotoxicity was observed with trastuzumab, several studies have addressed potential cardiac damage of trastuzumab itself and lapatinib. The differences in cardiovascular effects of these two compounds are somewhat unexpected and suggest distinct mechanisms of action, which have clear implications in clinical application and prevention of cardiotoxicity in cardio-oncological approaches.

Original languageEnglish
Pages (from-to)693-704
Number of pages12
JournalFuture Cardiology
Volume7
Issue number5
DOIs
Publication statusPublished - Sep 2011

Fingerprint

Breast Neoplasms
Antibodies, Monoclonal, Humanized
Neoplasms
Receptor Protein-Tyrosine Kinases
Epidermal Growth Factor Receptor
Cardiac Myocytes
Protein-Tyrosine Kinases
ErbB Receptors
Cardiotoxicity
Trastuzumab
Heart Diseases
Therapeutics
Lymph Nodes
Recurrence
Incidence
Pharmaceutical Preparations
lapatinib

Keywords

  • cardio-oncology
  • cardiotoxicity
  • HER receptors
  • lapatinib
  • prevention
  • trastuzumab

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Molecular Medicine

Cite this

Cardio-oncology in targeting the HER receptor family : The puzzle of different cardiotoxicities of HER2 inhibitors. / Albini, Adriana; Cesana, Eugenio; Donatelli, Francesco; Cammarota, Rosaria; Bucci, Eraldo O.; Baravelli, Massimo; Anzà, Claudio; Noonan, Douglas M.

In: Future Cardiology, Vol. 7, No. 5, 09.2011, p. 693-704.

Research output: Contribution to journalArticle

@article{9c1a08584e8e4cc48fb0097471b76ab8,
title = "Cardio-oncology in targeting the HER receptor family: The puzzle of different cardiotoxicities of HER2 inhibitors",
abstract = "The HER family of tyrosine kinase receptors includes several members that are clinically important targets in cancer therapies, in particular HER1 (the EGF receptor) and HER2, other members include HER3 and HER4. Trastuzumab, a humanized monoclonal antibody and lapatinib, a tyrosine kinase inhibitor, are drugs that target HER2, which is highly expressed in 20-30{\%} of breast cancers. Trastuzumab is recommended as an adjuvant therapy for lymph node positive, HER2-positive breast cancers, or node-negative cancer with high-risk of recurrence, as well as in stage IV cancers. One serious side effect of trastuzumab is cardiomyocyte dysfunction, resulting in reduced heart contractile efficiency. The incidence of collateral effects on the heart with trastuzumab therapy increases in people with cardiovascular risk factors, heart disease and when combined with other chemotherapeutics. When cardiotoxicity was observed with trastuzumab, several studies have addressed potential cardiac damage of trastuzumab itself and lapatinib. The differences in cardiovascular effects of these two compounds are somewhat unexpected and suggest distinct mechanisms of action, which have clear implications in clinical application and prevention of cardiotoxicity in cardio-oncological approaches.",
keywords = "cardio-oncology, cardiotoxicity, HER receptors, lapatinib, prevention, trastuzumab",
author = "Adriana Albini and Eugenio Cesana and Francesco Donatelli and Rosaria Cammarota and Bucci, {Eraldo O.} and Massimo Baravelli and Claudio Anz{\`a} and Noonan, {Douglas M.}",
year = "2011",
month = "9",
doi = "10.2217/fca.11.54",
language = "English",
volume = "7",
pages = "693--704",
journal = "Future Cardiology",
issn = "1479-6678",
publisher = "Future Medicine Ltd.",
number = "5",

}

TY - JOUR

T1 - Cardio-oncology in targeting the HER receptor family

T2 - The puzzle of different cardiotoxicities of HER2 inhibitors

AU - Albini, Adriana

AU - Cesana, Eugenio

AU - Donatelli, Francesco

AU - Cammarota, Rosaria

AU - Bucci, Eraldo O.

AU - Baravelli, Massimo

AU - Anzà, Claudio

AU - Noonan, Douglas M.

PY - 2011/9

Y1 - 2011/9

N2 - The HER family of tyrosine kinase receptors includes several members that are clinically important targets in cancer therapies, in particular HER1 (the EGF receptor) and HER2, other members include HER3 and HER4. Trastuzumab, a humanized monoclonal antibody and lapatinib, a tyrosine kinase inhibitor, are drugs that target HER2, which is highly expressed in 20-30% of breast cancers. Trastuzumab is recommended as an adjuvant therapy for lymph node positive, HER2-positive breast cancers, or node-negative cancer with high-risk of recurrence, as well as in stage IV cancers. One serious side effect of trastuzumab is cardiomyocyte dysfunction, resulting in reduced heart contractile efficiency. The incidence of collateral effects on the heart with trastuzumab therapy increases in people with cardiovascular risk factors, heart disease and when combined with other chemotherapeutics. When cardiotoxicity was observed with trastuzumab, several studies have addressed potential cardiac damage of trastuzumab itself and lapatinib. The differences in cardiovascular effects of these two compounds are somewhat unexpected and suggest distinct mechanisms of action, which have clear implications in clinical application and prevention of cardiotoxicity in cardio-oncological approaches.

AB - The HER family of tyrosine kinase receptors includes several members that are clinically important targets in cancer therapies, in particular HER1 (the EGF receptor) and HER2, other members include HER3 and HER4. Trastuzumab, a humanized monoclonal antibody and lapatinib, a tyrosine kinase inhibitor, are drugs that target HER2, which is highly expressed in 20-30% of breast cancers. Trastuzumab is recommended as an adjuvant therapy for lymph node positive, HER2-positive breast cancers, or node-negative cancer with high-risk of recurrence, as well as in stage IV cancers. One serious side effect of trastuzumab is cardiomyocyte dysfunction, resulting in reduced heart contractile efficiency. The incidence of collateral effects on the heart with trastuzumab therapy increases in people with cardiovascular risk factors, heart disease and when combined with other chemotherapeutics. When cardiotoxicity was observed with trastuzumab, several studies have addressed potential cardiac damage of trastuzumab itself and lapatinib. The differences in cardiovascular effects of these two compounds are somewhat unexpected and suggest distinct mechanisms of action, which have clear implications in clinical application and prevention of cardiotoxicity in cardio-oncological approaches.

KW - cardio-oncology

KW - cardiotoxicity

KW - HER receptors

KW - lapatinib

KW - prevention

KW - trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=80053095476&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053095476&partnerID=8YFLogxK

U2 - 10.2217/fca.11.54

DO - 10.2217/fca.11.54

M3 - Article

C2 - 21929348

AN - SCOPUS:80053095476

VL - 7

SP - 693

EP - 704

JO - Future Cardiology

JF - Future Cardiology

SN - 1479-6678

IS - 5

ER -